Acrux (ASX:ACR) and its partner, TruPharma, rolled out a 90-gram pack of Dapsone 5% Gel in the US, according to a Thursday filing with the Australian bourse.
Dapsone 5% Gel is a topical prescription medicine to treat acne vulgaris, per the filing.
Annual market sales for the product reached more than $15.8 million in the 12 months ended August 2024.